Rituximab in steroid-refractory immune-related pancreatitis: a case report
The use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1205720/full |
| _version_ | 1797768470514892800 |
|---|---|
| author | Armando Santoro Armando Santoro Silvia Masini Silvia Masini Raffaele Cavina Maria Chiara Tronconi Fabio De Vincenzo |
| author_facet | Armando Santoro Armando Santoro Silvia Masini Silvia Masini Raffaele Cavina Maria Chiara Tronconi Fabio De Vincenzo |
| author_sort | Armando Santoro |
| collection | DOAJ |
| description | The use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in the setting of relapsing non-ICI-induced autoimmune pancreatitis. However, its use has not been tested for treating immunotherapy-related pancreatitis. Here, we present the case of a patient with steroid-refractory immune-related pancreatitis successfully treated with rituximab as a potential strategy for irAE management. |
| first_indexed | 2024-03-12T20:54:14Z |
| format | Article |
| id | doaj.art-2d15be14dfa74d859193b42bd4ab04a2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T20:54:14Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2d15be14dfa74d859193b42bd4ab04a22023-07-31T21:43:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-07-011310.3389/fonc.2023.12057201205720Rituximab in steroid-refractory immune-related pancreatitis: a case reportArmando Santoro0Armando Santoro1Silvia Masini2Silvia Masini3Raffaele Cavina4Maria Chiara Tronconi5Fabio De Vincenzo6Department of Biomedical Sciences, Humanitas University, Milan, ItalyIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Milan, ItalyIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, ItalyIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, ItalyIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, ItalyIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, ItalyThe use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in the setting of relapsing non-ICI-induced autoimmune pancreatitis. However, its use has not been tested for treating immunotherapy-related pancreatitis. Here, we present the case of a patient with steroid-refractory immune-related pancreatitis successfully treated with rituximab as a potential strategy for irAE management.https://www.frontiersin.org/articles/10.3389/fonc.2023.1205720/fullrituximabsteroid-refractory pancreatitisimmune-related adverse eventatezolizumabimmune checkpoint inhibitors |
| spellingShingle | Armando Santoro Armando Santoro Silvia Masini Silvia Masini Raffaele Cavina Maria Chiara Tronconi Fabio De Vincenzo Rituximab in steroid-refractory immune-related pancreatitis: a case report Frontiers in Oncology rituximab steroid-refractory pancreatitis immune-related adverse event atezolizumab immune checkpoint inhibitors |
| title | Rituximab in steroid-refractory immune-related pancreatitis: a case report |
| title_full | Rituximab in steroid-refractory immune-related pancreatitis: a case report |
| title_fullStr | Rituximab in steroid-refractory immune-related pancreatitis: a case report |
| title_full_unstemmed | Rituximab in steroid-refractory immune-related pancreatitis: a case report |
| title_short | Rituximab in steroid-refractory immune-related pancreatitis: a case report |
| title_sort | rituximab in steroid refractory immune related pancreatitis a case report |
| topic | rituximab steroid-refractory pancreatitis immune-related adverse event atezolizumab immune checkpoint inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1205720/full |
| work_keys_str_mv | AT armandosantoro rituximabinsteroidrefractoryimmunerelatedpancreatitisacasereport AT armandosantoro rituximabinsteroidrefractoryimmunerelatedpancreatitisacasereport AT silviamasini rituximabinsteroidrefractoryimmunerelatedpancreatitisacasereport AT silviamasini rituximabinsteroidrefractoryimmunerelatedpancreatitisacasereport AT raffaelecavina rituximabinsteroidrefractoryimmunerelatedpancreatitisacasereport AT mariachiaratronconi rituximabinsteroidrefractoryimmunerelatedpancreatitisacasereport AT fabiodevincenzo rituximabinsteroidrefractoryimmunerelatedpancreatitisacasereport |